Analysts maintain Overweight ratings on Alphatec despite lowering targets following disappointing first-quarter performance and product mix headwinds.
Barclays and Piper Sandler reduced their price targets on Alphatec Holdings (NASDAQ:ATEC) after first-quarter results missed expectations. Barclays cut its target to $24 from $27, while Piper Sandler lowered its to $14 from $25, both retaining Overweight ratings.
The downgrades follow softer-than-expected revenue per case and a weak EOS quarter, driven by unfavorable product mix. Despite near-term challenges, analysts remain bullish on ATEC’s long-term growth, citing its focus on spinal disorder solutions and surgical innovations.
Alphatec, a medical technology firm, develops implants and enabling technologies for spine surgery. The company’s five-year EPS forecast stands at 158.80%, reflecting optimism in its future prospects.